LANGHORNE, Pa. / Nov 13, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the below listed upcoming healthcare conferences and participating in fireside chats.
Jefferies London Healthcare Conference, November 19-21, 2024
Fireside Chat: November 20th, 1:00pm GT/8:00am ET/5:00am PT
Piper Sandler 36th Annual Healthcare Conference, December 3-5, 2024
Fireside Chat: December 3rd, 8:30am ET/5:30am PT
The live webcasts and subsequent replays will be available on the “Events & Presentations” section of the Company’s corporate website at https://savarapharma.com/investors/events-presentations/ and will be archived for 90 days.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, X: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.
| Last Trade: | US$2.10 |
| Daily Change: | 0.05 2.44 |
| Daily Volume: | 1,090,007 |
| Market Cap: | US$360.400M |
March 27, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
